mammamiabingo| Jinxin's reproductive growth exceeds 6%, Shanghai will include some assisted reproductive projects in medical insurance

Jinxin Reproductive (01951) rose by more than 6%. As of press time, it rose by 6mammamiabingo.27%, reported at HK$3.56, with a turnover of HK$51.461 million.

On the news front, recently, the Shanghai City Medical Insurance Bureau, together with the Human Resources and Social Security and the Health Department, issued the "Notice on Including Some Therapeutic Assisted Reproductive Technology Projects into the Coverage of Medical Insurance and Work Injury Insurance." Starting from June 1 this year, 12 Assisted reproductive medical service items will be included in the scope of medical insurance payment, covering necessary medical assisted reproductive technologies such as oocyte retrieval, sperm retrieval, artificial insemination, embryo culture, and embryo transfer. It is reported that since the beginning of this year, five provinces including Inner Mongolia, Gansu, Xinjiang, Shandong and Jiangxi have included assisted reproduction in medical insurance.

Southwest Securities pointed out that the assisted reproduction market has vast space and policies help increase industry penetration. According to the Sullivan Report, 2020mammamiabingoThe size of my country's assisted reproduction market is 43.4 billion yuan, and it is expected that the size of my country's assisted reproduction market will reach 85.4 billion yuan by 2025. Investment recommendation: Vertical comparison of medical service segments shows that assisted reproduction has high barriers and high profit margins. It is recommended to pay attention to assisted reproduction medical service institutions, including Jinxin Reproduction.